Side-by-side · Research reference
ARA 290vsGHK-Cu
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED17/59 cited
BHuman-MechanisticHUMAN-REVIEWED8/47 cited
GHK-Cu
Tripeptide · Skin / Hair / Wound Healing
SQ or topical · Local · Daily or 2-3×/week
01Mechanism of Action
Parameter
ARA 290
GHK-Cu
Primary target
Innate repair receptor (EPO receptor / CD131 heterodimer)
Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018
Pathway
EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades
Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018
Downstream effect
Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014Culver 2017
Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018Zink 2003
Feedback intact?
N/A — does not interact with hematopoietic EPO receptorLiu 2014
Replaces declining endogenous levels
Origin
11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties
Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018
Antibody development
Not reported in clinical trials
—
02Dosage Protocols
Parameter
ARA 290
GHK-Cu
Standard dose (Phase 2)
4 mg / dayBrines 2015Culver 2017
Sarcoidosis SFN and diabetic neuropathy trials.
—
Frequency
Once daily
Self-administered subcutaneously.
Daily or 2–3× per week (SQ)
Duration
28 days (Phase 2)Culver 2017
Corneal nerve improvements observed by day 28.
8–12 weeks for visible skin / hair effect
Evidence basis
Phase 2 RCTsCulver 2017Brines 2015
64-subject sarcoidosis trial, type 2 diabetes trial.
Human-mechanistic + topical clinical studiesPickart 2018
Timing
Any time of day
No circadian dependence reported.
No specific time; evening preferred for topicals
Standard SQ dose
—
1–2 mg / dayPickart 2018
Anecdotal injectable range; topical creams use 0.1–2% solutions.
Topical concentration
—
0.1–2.0% in serum / cream
Lower / starter dose
—
0.5 mg / day SQ
Reconstitution
—
Bacteriostatic water; light-protected
Half-life
—
Hours (estimated; rapid tissue uptake)
03Metabolic / Fat Loss Evidence
Parameter
ARA 290
GHK-Cu
Primary effect
Improved metabolic control (HbA1c, fasting glucose)Brines 2015
Secondary to neuropathy treatment; direct lipolytic effects not established.
—
HbA1c
Significant reduction vs placebo
Observed in type 2 diabetes + neuropathy trial.
—
Fasting glucose
Improved in ARA 290 group
—
Body composition
Not directly quantified
Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.
—
04Side Effects & Safety
Parameter
ARA 290
GHK-Cu
Injection site reaction
Mild, transient
Erythema, mild pruritus (common)
Hematopoiesis
None — non-erythropoietic
Distinguishes ARA 290 from native EPO.
—
Cardiovascular
No thrombotic events or hypertension reported
—
Immunogenicity
No antibody formation reported
—
Topical irritation
—
Mild redness, transient stinging
Copper accumulation
—
Theoretical with very high chronic doses
Allergic reaction
—
Rare hypersensitivity to copper
Pregnancy / OB
—
Avoid topical and SQ — insufficient data
Wilson disease
—
Contraindicated
Absolute Contraindications
ARA 290
- ·Hypersensitivity to ARA 290
GHK-Cu
- ·Wilson disease (copper-overload disorder)
- ·Pregnancy / breastfeeding
- ·Known copper hypersensitivity
Relative Contraindications
ARA 290
- ·Active malignancy (theoretical EPO-axis concern; not observed in trials)
GHK-Cu
- ·Hemochromatosis (copper-iron crosstalk theoretical)
- ·Concurrent copper-chelator therapy
05Administration Protocol
Parameter
ARA 290
GHK-Cu
1. Preparation
Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.
Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.
SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.
3. Timing
Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015
Anytime; evening preferred. Topical: apply to clean dry skin.
4. Dosing
4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.
5. Storage
Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.
30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.
06Stack Synergy
ARA 290
+ BPC-157
ModerateARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.
- ARA 290
- 4 mg SQ · daily
- BPC-157
- 250–500 mcg SQ · daily
- Frequency
- Once daily, same or separate injections
- Primary benefit
- Nerve regeneration, pain reduction, tissue healing
GHK-Cu
+ BPC-157
ModerateGHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.
- GHK-Cu
- 1–2 mg SQ · daily near wound
- BPC-157
- 250–500 mcg SQ · daily near wound
- Primary benefit
- Combined ECM rebuilding + angiogenesis for tissue repair